Chemistry:Litifilimab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | BDCA2 |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
Litifilimab is an investigational drug being evaluated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. It is an anti-BDCA2 monocolonal antibody.[1][2][3]
References
- ↑ "Litifilimab - Biogen". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800040410.
- ↑ "Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus". Expert Opinion on Investigational Drugs 32 (5): 345–353. May 2023. doi:10.1080/13543784.2023.2212154. PMID 37148249.
- ↑ "The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus". Immunotherapy. October 2023. doi:10.2217/imt-2023-0086. PMID 37877249.
 |  |
